Finally, high-throughput screening was demonstrated in an activity-based system that screened 1,022 small-molecule inhibitors in a genetically engineered model for Marfan syndrome (MFS), revealing glycogen synthase kinase 3 beta (GSK3β) as a positive hit among other interesting targets.66 Here, GSK3B is linked to Marfan syndrome.